Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Truist Securities Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21-REPORT RELEASED ON 19TH MARCH 2024

Author: Benzinga Newsdesk | March 20, 2024 08:46am
Truist Securities analyst Nicole Germino downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold and raises the price target from $11 to $21.

Posted In: FUSN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist